PPARG and glioblastoma: In clinical assessment, diabetic patients with glioblastoma treated with PPARγ agonists showed a longer median survival of 19 months, compared to 6 months in similar patients receiving the standard GBM treatment [6] PPARγ ligands could therefore be a potential drug for the treatment of glioblastoma [7].